{"id":"https://openalex.org/W2000253072","doi":"https://doi.org/10.1007/s40277-013-0027-2","title":"Coste-efectividad de dasatinib frente a dosis altas de imatinib y nilotinib en pacientes con leucemia mieloide cr\u00f3nica resistente a la dosis est\u00e1ndar de imatinib en Portugal","display_name":"Coste-efectividad de dasatinib frente a dosis altas de imatinib y nilotinib en pacientes con leucemia mieloide cr\u00f3nica resistente a la dosis est\u00e1ndar de imatinib en Portugal","publication_year":2013,"publication_date":"2013-12-19","ids":{"openalex":"https://openalex.org/W2000253072","doi":"https://doi.org/10.1007/s40277-013-0027-2","mag":"2000253072"},"language":"es","primary_location":{"id":"doi:10.1007/s40277-013-0027-2","doi":"https://doi.org/10.1007/s40277-013-0027-2","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s40277-013-0027-2","pdf_url":null,"source":{"id":"https://openalex.org/S2764754589","display_name":"PharmacoEconomics Spanish Research Articles","issn_l":"1695-405X","issn":["1695-405X","1989-5453"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["poland-20"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics Spanish Research Articles","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054608675","display_name":"Josep Darb\u00e0","orcid":"https://orcid.org/0000-0003-2371-0999","observed_orcids":["https://orcid.org/0000-0003-2371-0999"]},"institutions":[{"id":"https://openalex.org/I71999127","display_name":"Universitat de Barcelona","ror":"https://ror.org/021018s57","country_code":"ES","type":"education","lineage":["https://openalex.org/I71999127"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Josep Darb\u00e0","raw_affiliation_strings":["Departamento de Econom\u00eda, Universitat de Barcelona, Diagonal 690, 08034, Barcelona, Espa\u00f1a","Departamento de Econom\u00eda, Universitat de Barcelona, Barcelona, Espa\u00f1a"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departamento de Econom\u00eda, Universitat de Barcelona, Diagonal 690, 08034, Barcelona, Espa\u00f1a","institution_ids":["https://openalex.org/I71999127"]},{"raw_affiliation_string":"Departamento de Econom\u00eda, Universitat de Barcelona, Barcelona, Espa\u00f1a","institution_ids":["https://openalex.org/I71999127"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046467060","display_name":"Lisette Kaskens","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lisette Kaskens","raw_affiliation_strings":["BCN Health Economics & Outcomes Research, Barcelona, Espa\u00f1a"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BCN Health Economics & Outcomes Research, Barcelona, Espa\u00f1a","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074669185","display_name":"Manuel Abecassis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Manuel Abecassis","raw_affiliation_strings":["Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037981159","display_name":"Jo\u00e3o Carrasco","orcid":"https://orcid.org/0000-0001-7084-2674","observed_orcids":["https://orcid.org/0000-0001-7084-2674"]},"institutions":[{"id":"https://openalex.org/I4405254633","display_name":"Bristol-Myers Squibb (Portugal)","ror":"https://ror.org/0223rpe14","country_code":"PT","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405254633"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Joao Carrasco","raw_affiliation_strings":["Bristol-Myers Squibb, Pa\u00e7o de Arcos, Lisbon, Portugal","Bristol-Myers Squibb, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Pa\u00e7o de Arcos, Lisbon, Portugal","institution_ids":["https://openalex.org/I4405254633"]},{"raw_affiliation_string":"Bristol-Myers Squibb, Lisbon, Portugal","institution_ids":["https://openalex.org/I4405254633"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ricardo Vitorino","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254633","display_name":"Bristol-Myers Squibb (Portugal)","ror":"https://ror.org/0223rpe14","country_code":"PT","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405254633"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Ricardo Vitorino","raw_affiliation_strings":["Bristol-Myers Squibb, Pa\u00e7o de Arcos, Lisbon, Portugal","Bristol-Myers Squibb, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Pa\u00e7o de Arcos, Lisbon, Portugal","institution_ids":["https://openalex.org/I4405254633"]},{"raw_affiliation_string":"Bristol-Myers Squibb, Lisbon, Portugal","institution_ids":["https://openalex.org/I4405254633"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101708804","display_name":"Matthew J. Taylor","orcid":"https://orcid.org/0000-0003-3374-9598","observed_orcids":["https://orcid.org/0000-0003-3374-9598"]},"institutions":[{"id":"https://openalex.org/I52099693","display_name":"University of York","ror":"https://ror.org/04m01e293","country_code":"GB","type":"education","lineage":["https://openalex.org/I52099693"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Matthew Taylor","raw_affiliation_strings":["York Health Economics Consortium, University of York, York, Reino Unido"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"York Health Economics Consortium, University of York, York, Reino Unido","institution_ids":["https://openalex.org/I52099693"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5054608675"],"corresponding_institution_ids":["https://openalex.org/I71999127"],"apc_list":{"value":3140,"currency":"USD","value_usd":3140},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"11","issue":"3","first_page":"73","last_page":"83"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.5884000062942505,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.5884000062942505,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.38350000977516174,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.00419999985024333,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.9440000057220459},{"id":"https://openalex.org/keywords/nilotinib","display_name":"nilotinib","score":1.0},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.7590000033378601},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8180000185966492},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.8410000205039978},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8539999723434448},{"id":"https://openalex.org/keywords/accelerated-phase","display_name":"accelerated phase","score":0.47999998927116394},{"id":"https://openalex.org/keywords/blast-crisis","display_name":"blast crisis","score":0.8980000019073486},{"id":"https://openalex.org/keywords/portuguese-national-health-service","display_name":"Portuguese National Health Service","score":0.6330000162124634},{"id":"https://openalex.org/keywords/health-technology-assessment","display_name":"health technology assessment","score":0.5490000247955322},{"id":"https://openalex.org/keywords/drug-pricing","display_name":"drug pricing","score":0.3449999988079071},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.5320000052452087},{"id":"https://openalex.org/keywords/sensitivity-analysis","display_name":"sensitivity analysis","score":0.5550000071525574},{"id":"https://openalex.org/keywords/portugal","display_name":"Portugal","score":0.39800000190734863},{"id":"https://openalex.org/keywords/united-kingdom-comparison","display_name":"United Kingdom comparison","score":0.5460000038146973},{"id":"https://openalex.org/keywords/comparison-with-united-states","display_name":"United States comparison","score":0.6290000081062317}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7814085483551025},{"id":"https://openalex.org/C15708023","wikidata":"https://www.wikidata.org/wiki/Q80083","display_name":"Humanities","level":1,"score":0.5378431677818298},{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.5285227298736572},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.45653045177459717},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.38665035367012024},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.17900687456130981},{"id":"https://openalex.org/C142362112","wikidata":"https://www.wikidata.org/wiki/Q735","display_name":"Art","level":0,"score":0.0984569787979126},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.06379365921020508}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1007/s40277-013-0027-2","doi":"https://doi.org/10.1007/s40277-013-0027-2","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s40277-013-0027-2","pdf_url":null,"source":{"id":"https://openalex.org/S2764754589","display_name":"PharmacoEconomics Spanish Research Articles","issn_l":"1695-405X","issn":["1695-405X","1989-5453"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["poland-20"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics Spanish Research Articles","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9476000070571899}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":32,"referenced_works":["https://openalex.org/W46835818","https://openalex.org/W1571092422","https://openalex.org/W1970962784","https://openalex.org/W1980571402","https://openalex.org/W1982993780","https://openalex.org/W1991694315","https://openalex.org/W1999609638","https://openalex.org/W2006917576","https://openalex.org/W2009563819","https://openalex.org/W2019601163","https://openalex.org/W2023371823","https://openalex.org/W2028959752","https://openalex.org/W2038161969","https://openalex.org/W2044234769","https://openalex.org/W2044484102","https://openalex.org/W2053131280","https://openalex.org/W2057658564","https://openalex.org/W2060529741","https://openalex.org/W2098820223","https://openalex.org/W2100943317","https://openalex.org/W2106326841","https://openalex.org/W2107268345","https://openalex.org/W2110986726","https://openalex.org/W2158294624","https://openalex.org/W2171188310","https://openalex.org/W2242087004","https://openalex.org/W2314938037","https://openalex.org/W2493886745","https://openalex.org/W2523073325","https://openalex.org/W2563937343","https://openalex.org/W2566591588","https://openalex.org/W2579504722"],"related_works":["https://openalex.org/W1972567027","https://openalex.org/W7036196220","https://openalex.org/W2099657324","https://openalex.org/W1987001205","https://openalex.org/W7035934577","https://openalex.org/W7218136080","https://openalex.org/W2114853568","https://openalex.org/W2071417256","https://openalex.org/W2018101790","https://openalex.org/W2906094070"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}